CALL FOR PAPERS Biomarkers in Lung Diseases: from Pathogenesis to Prediction to New Therapies Molecular biomarkers in idiopathic pulmonary fibrosis
CALL FOR PAPERS Biomarkers in Lung Diseases: from Pathogenesis to Prediction to New Therapies Molecular biomarkers in idiopathic pulmonary fibrosis
复制标题
DOI：
--
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
B. Ley;K. Brown;H. Collard
中科院分区：
文献类型：
--
作者：
B. Ley;K. Brown;H. Collard
Ley B, Brown KK, Collard HR。特发性肺纤维化的分子生物标志物。[J] .中国生物医学工程学报，2016,31(2):387 - 398。2014年9月26日首次出版；doi: 10.1152 / ajplung.00014.2014。分子生物标志物在特发性肺纤维化（IPF）中是非常需要的，它们具有阐明潜在疾病机制，加速药物开发和推进临床管理的潜力。目前，还没有广泛用于IPF临床的分子生物标志物，对潜在标志物的研究仍处于起步阶段。已提出的IPF发病机制的核心机制包括肺泡上皮细胞功能障碍、免疫失调和纤维发生。有用的标记物反映了重要的病理途径，是实际和准确测量的，经过了广泛的验证，并且是对其预期用途的当前方法的改进。成功开发有用的分子生物标志物是未来IPF转化研究的核心挑战，需要各方共同努力，促进IPF患者的护理。
Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 307: L681–L691, 2014. First published September 26, 2014; doi:10.1152/ajplung.00014.2014.—Molecular biomarkers are highly desired in idiopathic pulmonary fibrosis (IPF), where they hold the potential to elucidate underlying disease mechanisms, accelerated drug development, and advance clinical management. Currently, there are no molecular biomarkers in widespread clinical use for IPF, and the search for potential markers remains in its infancy. Proposed core mechanisms in the pathogenesis of IPF for which candidate markers have been offered include alveolar epithelial cell dysfunction, immune dysregulation, and fibrogenesis. Useful markers reflect important pathological pathways, are practically and accurately measured, have undergone extensive validation, and are an improvement upon the current approach for their intended use. The successful development of useful molecular biomarkers is a central challenge for the future of translational research in IPF and will require collaborative efforts among those parties invested in advancing the care of patients with IPF.